Sionna Therapeutics
-
CG Life is a precision medicine launch agency that’s at the forefront of crafting compelling narratives for Life Science companies navigating the drug discovery process.
During my strategic communications internship at CG Life, I was tapped one day by SVP of PR, Karen Sharma, to craft a press release for Life Science client Sionna Therapeutics. The task? To come up with a release in 2 hours that generated excitement for their new Chief Business Officer Caroline Beer Stark, while aligning with Sionna’s brand tone.
-
Develop a dynamic, hype-building press release that spotlights a leading thought leader within pharma and life sciences
Ensure a consistent and authentic brand voice across all messaging, reinforcing the organization’s identity while elevating the thought leader’s credibility and influence.
Adhere to AP Style guidelines to maintain clarity, accuracy, and professionalism throughout the content.
-
Clarifying the Details – Began by meeting with SVP Karen Sharma to confirm all announcement specifics. Reviewed past client press-release packages and gathered key subject-matter quotes to ensure a complete understanding of the announcement’s context, tone, and strategic priorities before drafting.
Drafting the Narrative – Crafted a release designed to build excitement around a rising star and new addition to the Sionna Therapeutics team. Spotlighted her background, professional accomplishments, and forward-thinking vision for Sionna, ensuring the story positioned her as both a leader and a catalyst for the company’s future.
Finalizing for Impact – Prepared the polished version of the release for internal review across the client team, ensuring it was visually clean, strategically framed, and ready to support a broader communications strategy surrounding the announcement.
-
After a comprehensive information-gathering, drafting, and review process, I developed a client-ready press release under a tight two-hour window. By working cross-functionally with leadership, I was able to ideate a brand-aligned narrative, incorporate key c-suite quotes, and prepare the release for leadership review, helping me produce high-quality deliverables under time pressure.
The final release was published by the client via GlobeNewswire one month later, delivering measurable visibility for the announcement and reinforcing the impact of a coordinated, brand-conscious communications effort.
PRESS RELEASE
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO).
“We are delighted to welcome Caroline to our executive team at such a pivotal stage for Sionna,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “Caroline’s exceptional experience, leadership, and value creation mindset will enhance our corporate development efforts as we continue to advance toward our goal of delivering innovative and transformative therapies for people living with CF.”
Caroline brings over 20 years of experience in the life science industry to her role with Sionna. She was most recently CBO at Jnana Therapeutics until Jnana’s sale to Otsuka Pharmaceutical. Caroline led the team responsible for corporate and business development, alliance management, legal contracts, new product planning, and communications. Before Jnana, she spent over a decade at Alnylam Pharmaceuticals; in her final role there, she served as VP of Business Development. During this time, she led the formation of a variety of high-impact partnerships including a 5-year collaboration with Regeneron Pharmaceuticals to discover and develop new RNA interference (RNAi) therapeutics. Prior to Alnylam, Caroline served in business development at Amicus Therapeutics and started her career as a strategy consultant at Bain & Company. Caroline received her MBA from the MIT Sloan School of Management and a Bachelor of Economics from Duke University.
“I believe that the most meaningful growth happens in organizations where scientific excellence and business strategy work seamlessly together while focusing on the patient as the North-Star. Sionna embodies this approach, which is why I’m thrilled to join the company,” said Caroline. "I look forward to helping Sionna execute on its mission, striving toward enhanced options for CF patients.”
SIONNA THERAPEUTICS APPOINTS CAROLINE STARK BEER AS CHIEF BUSINESS OFFICER
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For information about Sionna, visit www.sionnatx.com.